Published in TB and Outbreaks Week, April 5th, 2005
According to a study from Scotland, "Acinetobacter baumannii is now one of the most frequently encountered nosocomial pathogens in intensive therapy units, and is renowned for being difficult to treat because of resistance to most antibiotics.
"Carbapenems are the remaining drugs of choice in many centers, but carbapenem resistance is now emerging in strains worldwide. Two subgroups of carbapenem-hydrolyzing beta-lactamases, which differ in their amino-acid homology, have been found in some resistant strains."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.